Trial Design
The study enrolled 450 participants with early-stage Alzheimer's disease across 60 research centers. Patients received either the experimental treatment or placebo for 18 months. Researchers assessed cognitive function, daily living abilities, and biomarker changes at regular intervals.
Findings
Participants receiving the treatment showed slower cognitive decline compared to the placebo group. Brain imaging revealed reduced accumulation of amyloid plaques, a hallmark of Alzheimer's pathology. The treatment appeared well-tolerated with manageable side effects reported.
Next Steps
Researchers plan to advance to a larger phase 3 trial with approximately 2,000 participants. Regulatory agencies will review the data to determine requirements for approval studies. If successful, the treatment could become available within three to four years.